| LARGE-GLOBAL-PHARMACEUTICAL-COMPANY |
LARGE-GLOBAL-PHARMACEUTICAL-COMPANY |
90%
|
Our largest customer represented a strategic partnership with a large global pharmaceutical company and contributed 7.7% of revenue for the year. |
| TMO |
Thermo Fisher Scientific Inc. |
85%
|
Reciprocal relationship from TMO graph: Reciprocal relationship from ICLR graph: Reciprocal relationship from TMO graph: Reciprocal relationship from ICLR graph: responsibility for the maintenance of… |
| TMO |
Thermo Fisher Scientific Inc. |
85%
|
responsibility for the maintenance of key client relationships. Our aim is to develop deeper relationships within our client base to gain repeat business and enable us new opportunities to penetrate … |
| BIOTEL-RESEARCH-LLC |
BIOTEL-RESEARCH-LLC |
62%
|
BioTel Research, LLC which comprised the business formerly known as Philips Pharma Solutions, a leading provider of medical imaging and cardiac safety monitoring services. On April 20, 2023, the Comp… |
| COMPANY-COUNTRY-GROUP |
COMPANY-COUNTRY-GROUP |
62%
|
guidelines, it could result in a material adverse effect. In addition, our failure to comply with applicable regulations and guidelines, depending on the extent of the failure, could result in fines,… |
| ICON-CLINICAL-RESEARCH-AUSTRIA-GMBH |
ICON-CLINICAL-RESEARCH-AUSTRIA-GMBH |
62%
|
guidelines, it could result in a material adverse effect. In addition, our failure to comply with applicable regulations and guidelines, depending on the extent of the failure, could result in fines,… |
| ICON-CLINICAL-RESEARCH-PTY-LIMITED |
ICON-CLINICAL-RESEARCH-PTY-LIMITED |
62%
|
guidelines, it could result in a material adverse effect. In addition, our failure to comply with applicable regulations and guidelines, depending on the extent of the failure, could result in fines,… |
| ICON-GROUP |
ICON-GROUP |
62%
|
ccounted for as a business combination using the acquisition method of accounting in accordance with ASC 805. In the years ended December 31, 2024, December 31, 2023 and December 31, 2022, the Compan… |
| ICON-INVESTMENTS-SIX-DESIGNATED-ACTIVITY-COMPANY |
ICON-INVESTMENTS-SIX-DESIGNATED-ACTIVITY-COMPANY |
62%
|
ting to $ 500.0 million and $ 202.0 million respectively as of the date of acquisition, becoming fully amortized on July 1, 2024. On August 19, 2024, the Company acquired KCR. The acquisition resulte… |
| INDIGO-MERGER-SUB-INC |
INDIGO-MERGER-SUB-INC |
62%
|
ting to $ 500.0 million and $ 202.0 million respectively as of the date of acquisition, becoming fully amortized on July 1, 2024. On August 19, 2024, the Company acquired KCR. The acquisition resulte… |
| KCR-CRO-PTY-LTD |
KCR-CRO-PTY-LTD |
62%
|
guidelines, it could result in a material adverse effect. In addition, our failure to comply with applicable regulations and guidelines, depending on the extent of the failure, could result in fines,… |
| KCR-GROUP |
KCR-GROUP |
62%
|
cember 31, 2023: 47 days, September 30, 2023: 49 days, June 30, 2023: 52 days). A decrease in the number of days’ revenue outstanding during a period will result in cash inflows to the Company while … |
| KCR-S-A-GROUP |
KCR-S-A-GROUP |
62%
|
onally, the SEC maintains a website (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Our service o… |
| MEDPASS-INTERNATIONAL-PTY-LTD |
MEDPASS-INTERNATIONAL-PTY-LTD |
62%
|
guidelines, it could result in a material adverse effect. In addition, our failure to comply with applicable regulations and guidelines, depending on the extent of the failure, could result in fines,… |
| OBLIGOR-GROUP |
OBLIGOR-GROUP |
62%
|
he application of these critical accounting estimates is discussed with the Audit Committee of the Board of Directors. Revenue Recognition - Clinical Trial Services Clinical trial services are a sing… |
| ONCACARE-LIMITED |
ONCACARE-LIMITED |
62%
|
ccounted for as a business combination using the acquisition method of accounting in accordance with ASC 805. In the years ended December 31, 2024, December 31, 2023 and December 31, 2022, the Compan… |
| PHARMACEUTICAL-RESEARCH-ASSOCIATES-PTY-LIMITED |
PHARMACEUTICAL-RESEARCH-ASSOCIATES-PTY-LIMITED |
62%
|
guidelines, it could result in a material adverse effect. In addition, our failure to comply with applicable regulations and guidelines, depending on the extent of the failure, could result in fines,… |
| PLEDGOR-GROUP |
PLEDGOR-GROUP |
62%
|
he application of these critical accounting estimates is discussed with the Audit Committee of the Board of Directors. Revenue Recognition - Clinical Trial Services Clinical trial services are a sing… |
| PRA-HEALTH-SCIENCES-INC |
PRA-HEALTH-SCIENCES-INC |
62%
|
ting to $ 500.0 million and $ 202.0 million respectively as of the date of acquisition, becoming fully amortized on July 1, 2024. On August 19, 2024, the Company acquired KCR. The acquisition resulte… |
| RPS-BERMUDA-LTD |
RPS-BERMUDA-LTD |
62%
|
guidelines, it could result in a material adverse effect. In addition, our failure to comply with applicable regulations and guidelines, depending on the extent of the failure, could result in fines,… |
| RPS-RESEARCH-AUSTRIA-GMBH |
RPS-RESEARCH-AUSTRIA-GMBH |
62%
|
guidelines, it could result in a material adverse effect. In addition, our failure to comply with applicable regulations and guidelines, depending on the extent of the failure, could result in fines,… |
